Incyte (WBO:INCY) FCF Margin %

: 14.35% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Incyte's Free Cash Flow for the three months ended in Dec. 2023 was €133 Mil. Incyte's Revenue for the three months ended in Dec. 2023 was €929 Mil. Therefore, Incyte's FCF Margin % for the quarter that ended in Dec. 2023 was 14.35%.

As of today, Incyte's current FCF Yield % is 3.79%.

The historical rank and industry rank for Incyte's FCF Margin % or its related term are showing as below:

WBO:INCY' s FCF Margin % Range Over the Past 10 Years
Min: -13.28 Med: 13.06 Max: 29.3
Current: 12.08

During the past 13 years, the highest FCF Margin % of Incyte was 29.30%. The lowest was -13.28%. And the median was 13.06%.

WBO:INCY's FCF Margin % is ranked better than
88.36% of 1031 companies
in the Biotechnology industry
Industry Median: -149.63 vs WBO:INCY: 12.08

Incyte FCF Margin % Historical Data

The historical data trend for Incyte's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

29.30

-11.70

19.04

26.28

12.15

Incyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %																28.31	-16.39	31.34	14.89	14.35

Competitive Comparison

For the Biotechnology subindustry, Incyte's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incyte FCF Margin % Distribution

For the Biotechnology industry and Healthcare sector, Incyte's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Incyte's FCF Margin % falls into.

Incyte FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Incyte's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	411.734	/	3388.91
	=	12.15 %

Incyte's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	133.388	/	929.234
	=	14.35 %

Incyte FCF Margin % Related Terms

Thank you for viewing the detailed overview of Incyte's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (WBO:INCY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (WBO:INCY) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.